ArticleScientific reports2025
High-resolution genomic and molecular characterization of vancomycin-resistant enterococci from hospitalized patients in a tertiary care center in Riyadh, Saudi Arabia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Vancomycin-resistant enterococci (VRE), particularly Enterococcus faecium, represent a significant nosocomial threat worldwide. In Saudi Arabia, limited genomic data exist to support phenotypic surveillance findings, impeding the understanding of resistance mechanisms, clonal diversity, and plasmid dynamics. To investigate the genomic and phenotypic characteristics of vancomycin-resistant E. faecium and E. faecalis clinical isolates from a tertiary care center in Riyadh, Saudi Arabia, and to assess antimicrobial resistance genes, virulence factors, sequence types, and plasmid replicons. Seventy-five VRE isolates were collected between 2017 and 2019 and subjected to antimicrobial susceptibility testing per CLSI guidelines. The whole genome sequencing (WGS) was performed using the Illumina MiSeq platform. Species identification, MLST/cgMLST typing, resistome, virulome, and plasmidome analyses were conducted using established bioinformatics pipelines (e.g., CARD, VFDB, PlasmidFinder, pyMLST). Among 75 isolates, 50 E. faecium and 6 E. faecalis passed WGS quality thresholds. E. faecium isolates showed high resistance to vancomycin (100%), ciprofloxacin (98%), and ampicillin (96%), while linezolid retained activity (98% susceptible). The vanA gene was detected in 93.9% of E. faecium isolates; other resistance determinants included tet(M), erm(B), and liaR/liaS mutations associated with daptomycin non-susceptibility. MLST revealed multiple STs, including ST136, ST102, and ST252, with no dominant clone, supporting polyclonality. Plasmid analysis identified 20 replicon types, predominantly rep11a, rep2, and repUS15, some co-associated with AMR genes. Virulence profiling showed enrichment of bopD, acm, and cpsA/uppS genes. E. faecalis isolates exhibited limited resistance and no clonal clustering. This is the most comprehensive genomic study of VRE from Saudi Arabia to date. Our findings reveal a diverse, polyclonal population of E. faecium harboring high-risk resistance and virulence determinants disseminated via plasmids. These data underscore the need for routine genomic surveillance to guide infection control and antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.